Dexmedetomidine Reduces Postoperative Delirium Following Cardiac Surgery
A systematic review and meta-analysis of 31 RCTs in Anaesthesia Critical Care & Pain Medicine evaluated the efficacy of dexmedetomidine (DEX) in preventing delirium after cardiac surgery. Delirium incidence was significantly lower in the DEX group compared with placebo or other treatments (RR, 0.61; 95% CI, 0.49-0.75; P < 0.001). This protective effect remained across subgroup analyses based on age, control type, delirium assessment method, and after excluding trials at high risk of bias. DEX use was associated with a shorter ICU length of stay (MD, –0.14 days; 95% CI, –1.28 to –0.04; P < 0.01). Trial sequential analysis confirmed the result's robustness. However, DEX increased bradycardia risk (RR, 1.53; 95% CI, 1.05-2.21; P = 0.02). No significant differences were found in mortality, intubation duration, hospital length of stay, atrial fibrillation, or hypotension.